Prescription medication · Rho Kinase Inhibitor (Ophthalmic)
netarsudil
Also sold as Rhopressa. Rhopressa is used to lower high pressure inside the eye.
Data updated 2026-05-15
- 1,797
- FDA reportsRarely reported
- $124.50
- Brand price (NADAC)
netarsudil (Rhopressa) is a prescription Rho Kinase Inhibitor (Ophthalmic). Rhopressa is used to lower high pressure inside the eye.
Rhopressa is an eye drop medicine. It helps lower pressure in the eye.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$124.50/unit
Generic Available
No
ALCON LABS INC
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Rhopressa is used to lower high pressure inside the eye.
Common side effects
Eye redness (53%), Corneal verticillata (20%), Pain where the drop is applied (20%)
Key warnings
Some patients have developed swelling of the cornea while using Rhopressa.
The sections below are summarized in plain English from netarsudil's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Rhopressa belongs to a class of drugs called Rho kinase inhibitors. It works by helping fluid drain better from the eye. This lowers the pressure inside the eye.
Side Effects (from patient reports)
Based on 1,797 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for netarsudil, by number of reports
- Conjunctival Hyperaemia
Conjunctival Hyperaemia
244 reports
- Vision Blurred
Vision Blurred
149 reports
- Eye Pain
Eye Pain
134 reports
- Ocular Hyperaemia
Ocular Hyperaemia
133 reports
- Eye Irritation
Eye Irritation
109 reports
- Corneal Oedema 95
Corneal Oedema
95 reports
- Intraocular Pressure Increased 88
Intraocular Pressure Increased
88 reports
- Visual Acuity Reduced 88
Visual Acuity Reduced
88 reports
- Lacrimation Increased 87
Lacrimation Increased
87 reports
- Eye Pruritus 64
Eye Pruritus
64 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for netarsudil each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where netarsudil sits
netarsudil has more FDA adverse-event reports than 11% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is netarsudil; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 1,797 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2017–2025.
Total Reports
1,797
Reports Mentioning Death
56
3.1% of reports — not proof of cause
Hospitalization Reports
97
Top Indication
Glaucoma
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | CONJUNCTIVAL HYPERAEMIA | 244 |
| 2 | VISION BLURRED | 149 |
| 4 | EYE PAIN | 134 |
| 5 | OCULAR HYPERAEMIA | 133 |
| 6 | EYE IRRITATION | 109 |
| 7 | CORNEAL OEDEMA | 95 |
| 8 | INTRAOCULAR PRESSURE INCREASED | 88 |
| 9 | VISUAL ACUITY REDUCED | 88 |
| 10 | LACRIMATION INCREASED | 87 |
| 13 | EYE PRURITUS | 64 |
| 14 | CORNEA VERTICILLATA | 59 |
| 15 | HEADACHE | 53 |
| 16 | DEATH | 49 |
| 17 | FATIGUE | 43 |
| 18 | VISUAL IMPAIRMENT | 42 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Some patients have developed swelling of the cornea while using Rhopressa. Tell your doctor if you have eye pain or vision changes. Using multi-dose bottles of eye drops can sometimes cause bacterial infections of the cornea.
Common Questions
What if I wear contact lenses?
Can I use Rhopressa more than once a day?
What should I do if my eyes get irritated?
How long does Rhopressa take to work?
Is Rhopressa safe for children?
Can elderly patients use Rhopressa?
What is the strength of Rhopressa?
What if the bottle is left at room temperature during shipping?
What is corneal verticillata?
What if I use too much Rhopressa?
What are the common side effects of netarsudil?
What drug class is netarsudil?
What pregnancy or breastfeeding source fields are listed for netarsudil?
Related Medications in Rho Kinase Inhibitor (Ophthalmic)
Other drugs grouped near netarsudil - same-class peers and common alternatives.
aflibercept
Eylea
AHZANTIVE is a medicine used to treat certain eye problems.
Compare with netarsudil →
artificial tears
Refresh, Systane
Artificial tears are eye drops that lubricate your eyes.
Compare with netarsudil →
bevacizumab (ophthalmic)
Avastin
Avastin is a medicine that blocks a protein called vascular endothelial growth factor (VEGF).
Compare with netarsudil →
bimatoprost
Lumigan
Bimatoprost eye drops help lower pressure in the eye.
Compare with netarsudil →
brimonidine ophthalmic
Alphagan P
Alphagan P eye drops help lower pressure in the eye.
Compare with netarsudil →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for netarsudil: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 1,797.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 3.12%.
- azelastine Δ 0.01 pts · 16,672 reports · Antihistamine (Nasal) 3.13%death share
- guanfacine Δ 0.03 pts · 7,386 reports · Central Alpha-2 Agonist 3.09%death share
- conjugated estrogens Δ 0.04 pts · 57,675 reports · Conjugated Estrogen 3.08%death share
- biotin Δ 0.07 pts · 29,879 reports · Vitamin B7 Supplement 3.05%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on netarsudil
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for netarsudil
The FDA label for netarsudil (sold under brand names such as Rhopressa) classifies it as a prescription-only medication in the Rho Kinase Inhibitor (Ophthalmic) class. Rhopressa is used to lower high pressure inside the eye. Official labeling lists 4 commonly reported side effects, including Eye redness (53%), Corneal verticillata (20%), Pain where the drop is applied (20%).
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,797 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: January 20, 2026
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages